Diagnosis and Evaluation of Myositis

Introduction to Myositis Evaluation

The American College of Rheumatology suggests that understanding CK/CPK levels is critical for distinguishing true myositis from myalgia-like syndromes, with CK/CPK levels being a key diagnostic factor 1, 2, 3

Myositis typically shows markedly elevated CK levels, with a median of approximately 2650 IU/L, indicating actual muscle damage with rhabdomyolysis, requiring urgent evaluation for life-threatening complications including myocarditis 2
Elevation of CK levels suggests myositis, and patients should be evaluated for life-threatening complications, with the European League Against Rheumatism recommending immediate initiation of high-dose corticosteroids in cases of markedly elevated CK (>3x normal) with weakness 3, 2
Even with elevated CK, muscle biopsy remains a crucial diagnostic tool when diagnosis is uncertain, as recommended by the American College of Rheumatology 4

Polymyalgia rheumatica-like syndrome presents with severe myalgia and fatigue but CK levels remain within normal limits, distinguishing it from true myositis, according to the American College of Rheumatology 1, 5, 6
Normal CK does not completely rule out myositis, as amyopathic or hypomyopathic dermatomyositis can present with normal or only mildly elevated CK despite active muscle inflammation, highlighting the need for a comprehensive diagnostic approach 4

The American College of Rheumatology recommends measuring CK/CPK immediately along with inflammatory markers (ESR, CRP) to assess disease activity, and considering additional muscle enzymes (AST, ALT, LDH, aldolase) if CK is normal but clinical suspicion remains high 1, 5, 4
If CK is markedly elevated (>3x normal) with weakness, the European Society for Medical Oncology suggests initiating high-dose corticosteroids immediately and searching for life-threatening manifestations, with a mortality rate of approximately 20% in checkpoint inhibitor-related myositis cases 3, 7, 2